Grunewald GL, Pleiss MA, Rafferty MF. Conformational preferences of dopamine analogues for inhibition of norepinephrine N-methyltransferase. Conformationally defined adrenergic agents.
Life Sci 1982;
31:993-1000. [PMID:
7132559 DOI:
10.1016/0024-3205(82)90171-0]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A series of analogues of dopamine (DA) with varying degrees of conformational flexibility have been examined as potential substrates or competitive inhibitors of the enzyme norepinephrine N-methyltransferase (NMT). A conformationally defined (rigid) analogue of the fully extended conformation of DA, 2-amino-6,7-dihydroxybenzonorbornene hydrobromide (3; 6,7-D2HX) proved to be a better substrate than the non-catechol parent 2-aminobenzonorbornene (4; 2HX). However, analogues 3 and 4 displayed equivalent competitive inhibitory activity toward phenylethanolamine (PEA). Neither 6,7-ADTN (5), a DA analogue in the 2-aminotetralin (2AT) system, nor 6,7-DTHIQ (7), a DA analogue in the tetrahydroisoquinoline (THIQ) system, showed substrate activity; 6,7-ADTN was a poorer competitive inhibitor than the parent 2AT but 6,7-DTHIQ was a better competitive inhibitor than its parent, THIQ (8). A tricyclic conformationally defined analogue 9 of 6,7-ADTN was devoid of either substrate or inhibitory activity. From these results it may be concluded that a fully extended side chain conformation is required for NMT substrate activity, and the better substrate activity for 6,7-D2HX compared to 4 is consistent with a proper catechol orientation for interaction with the norepinephrine (NE) binding site of NMT.
Collapse